Strategic Transactions
Deals In Depth: June/July 2016
Celgene and Novartis each signed $3 billion immuno-oncology deals, with Jounce and Xencor, respectively; Galenica Group made a $1.5 billion acquisition for a hyperkalaemia drug. Public financings grew from May to July in the biopharma industry, but decreased month over month in the device sector.
More from Deal-Making
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
An interactive look at pharma, medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
More from In Vivo
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.